Tag Archives: teva

Sale Rumor, Drugs Launch Boost High-Rated Mylan Stock

Mylan (MYL) stock broke out Wednesday as rumors circulated on Twitter that the generic and branded drugmaker might be for sale, possibly to Teva, and as it announced three drug launches. Mylan stock rose 6.7% Wednesday to 59, briefly passing a buy point of 59.70 before easing, and Teva Pharmaceutical Industries (TEVA) gained 2.5%. Analysts were divided about the logic of Teva acquiring Mylan, a competitor in generic drugs. BMO Capital Markets

Teva Upgraded On Strength Of Copaxone MS Drug

Sterne Agee upgraded Israeli drug giant Teva Pharmaceutical Industries (TEVA) to buy from neutral Friday, saying the outlook for its multiple-sclerosis drug Copaxone is better than most investors think. Teva issued 2015 guidance on Thursday morning, with revenue slightly below expectations but EPS on the high side. The 2015 revenue guidance of $19 billion to $19.4 billion is down from the current 2014 consensus estimate of $20.3 billion based on

Teva Acquiring Labrys Biologics For Migraine Drug

Israeli specialty-drug giant Teva Pharmaceutical Industries (TEVA) said Tuesday that it’s agreed to buy privately held Labrys Biologics, gaining a migraine drug that it expects to be a blockbuster. Teva agreed to pay $200 million upfront for Labrys, plus up to $625 million in milestone payments as Labrys’ drug LBR-101 works its way through the approval process